FDA-cleared profile

FlightPlan for Liver

GE Medical Systems SCS · Fluoroscopy/Angiography · FDA-cleared (510(k))

Authorized purpose: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.

Clinical role
Post-processing software for liver 3D X-ray angiography (CBCT) images that semi-automatically segments the liver arterial tree from an operator-defined starting point; its output is an adjunct physicians may use to evaluate hepatic arterial anatomy when planning embolization procedures.
Images and patients
Fluoroscopy/Angiography · Liver; hepatic arterial vasculature and hypervascular liver lesions
Key limitation
Keep in mind: Adjunct for the planning phase of liver embolization; pediatric applicability is unknown from the supplied FDA packet.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
  • Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Liver; hepatic arterial vasculature and hypervascular liver lesions Input: Contrast-injected 3D X-ray angiography or CBCT liver images; other studies may be reviewed side by side but are not the primary catalog modality.
  • Who uses it?Intended users: Physicians.
  • What does the software produce?Output: Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.
  • What is its most important limitation?Key limitation: Adjunct for the planning phase of liver embolization; pediatric applicability is unknown from the supplied FDA packet.

Clinical takeaway. Clinical role: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.

Evidence takeaway. Evidence from the reviewed source record: FDA-reported design-control and bench testing plus clinical assessment of paired CBCT studies by interventional radiologists using a five-point Likert scale; no sensitivity or specificity endpoint was stated.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Post-processing software for liver 3D X-ray angiography (CBCT) images that semi-automatically segments the liver arterial tree from an operator-defined starting point; its output is an adjunct physicians may use to evaluate hepatic arterial anatomy when planning embolization procedures.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "FlightPlan for Liver is a post processing software package that helps the analysis of 3D X-ray angiography images of the liver." … "Semi‐automatic segmentation of the liver arterial tree from an operator‐defined starting point in the CBCT images.". Read from the exact FDA decision document on 2026-11-14.

Required input
Contrast-injected 3D X-ray angiography or CBCT liver images; other studies may be reviewed side by side but are not the primary catalog modality.
  • Exact FDA submission
  • Checked 2026-09-19

FDA packet primary and secondary image scope.

Output and clinician action
Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.
  • Exact FDA submission
  • Checked 2026-09-19

FDA packet output scope.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Physicians.
  • Exact FDA submission
  • Checked 2026-09-19

FDA packet intended-user statement.

Limitations
Adjunct for the planning phase of liver embolization; pediatric applicability is unknown from the supplied FDA packet.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA workflow boundary; no pediatric exclusion was stated in the supplied text.

Evidence summary
FDA-reported design-control and bench testing plus clinical assessment of paired CBCT studies by interventional radiologists using a five-point Likert scale; no sensitivity or specificity endpoint was stated.
  • Exact FDA submission
  • Checked 2026-09-19

Submission evidence only.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA-reported design-control and bench testing plus clinical assessment of paired CBCT studies by interventional radiologists using a five-point Likert scale; no sensitivity or specificity endpoint was stated.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Submission evidence only.

Reported sensitivity
N/A- not diagnostic application
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
N/A- not diagnostic application
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Liver ASSIST Virtual Parenchyma regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionvxtl_17.0-4.24
  • IndependenceIndependence not established

K210807

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210807. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Contrast-injected 3D X-ray angiography or CBCT liver images; other studies may be reviewed side by side but are not the primary catalog modality.

    Scope: Exact FDA submission. FDA packet primary and secondary image scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K210807: FlightPlan for Liver

  2. Routing

    Source context, not route validation: The exact FDA package describes CBCT images as input, saving of results with optional export to GE's Vision application for 3D road-mapping, and compliance with the NEMA PS 3.1-3.20 (2016) DICOM standard. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "is a post‐processing, software‐only application using 3D X‐ray angiography images (CBCT) as input." … "Saving of results and export optionally to GE’s Vision application [K092639] for 3D road‐mapping.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K210807: FlightPlan for Liver

  3. AI processing

    Source context, not route validation: The exact FDA package describes FlightPlan for Liver as post-processing software that operates on GE's Advantage Workstation and AW Server platforms as an extension to the Volume Viewer application. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "is a post‐processing, software‐only application using 3D X‐ray angiography images (CBCT) as input." … "The software operates on GE’s Advantage Workstation [K110834] platform and AW Server [K081985] platform and is an extension to the GE’s Volume Viewer application". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K210807: FlightPlan for Liver

  4. Returned objects

    Source context, not route validation: Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K210807: FlightPlan for Liver

  5. Viewer/worklist/report

    Unresolved route: Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K210807: FlightPlan for Liver

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes FlightPlan for Liver as post-processing software that operates on GE's Advantage Workstation and AW Server platforms as an extension to the Volume Viewer application. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "is a post‐processing, software‐only application using 3D X‐ray angiography images (CBCT) as input." … "The software operates on GE’s Advantage Workstation [K110834] platform and AW Server [K081985] platform and is an extension to the GE’s Volume Viewer application". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes CBCT images as input, saving of results with optional export to GE's Vision application for 3D road-mapping, and compliance with the NEMA PS 3.1-3.20 (2016) DICOM standard. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "is a post‐processing, software‐only application using 3D X‐ray angiography images (CBCT) as input." … "Saving of results and export optionally to GE’s Vision application [K092639] for 3D road‐mapping.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Supported acquisition environment

Supported hardware: Email 1 November 6

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for FlightPlan for Liver; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K210807
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Fluoroscopy/Angiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Controlled catalog enum; exact primary input is 3D X-ray angiography/CBCT.

Anatomy
Liver; hepatic arterial vasculature and hypervascular liver lesions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA anatomy and lesion-vicinity scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-10-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K210807 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K210807: FlightPlan for Liver

    U.S. Food and Drug Administration - Published 2021-10-22 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Liver ASSIST Virtual Parenchyma model card (K210807)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K210807

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K210807 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K160088

Cydar EV

Cydar Ltd.

Authorized purpose: Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.

Modality
Fluoroscopy/Angiography
Anatomy
Lower thorax, abdomen, and pelvis; iliac vessels and corresponding veins
Decision
2016-07-07
FDA-cleared K260077

OrthoGrid Hip AI® 4.0

OrthoGrid Systems, Inc.

Authorized purpose: OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.

Modality
Fluoroscopy/Angiography
Anatomy
Hip
Decision
2026-05-29
FDA-cleared K252503

Intelligent NR

Canon, Inc.

Authorized purpose: Canon Intelligent NR is a noise-reduction function for fluoroscopic images acquired on compatible Canon radiography and fluoroscopy systems.

Modality
Fluoroscopy/Angiography
Anatomy
Whole body; diagnostic and interventional anatomy
Decision
2026-04-30
FDA-cleared K252099

Trinias

Shimadzu Corporation

Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.

Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Decision
2026-03-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history